InBio, Charlottesville, Va.
Michigan State University, East Lansing, Mich; University of South Carolina, Columbia, SC.
J Allergy Clin Immunol. 2024 Aug;154(2):447-457. doi: 10.1016/j.jaci.2024.04.017. Epub 2024 Apr 30.
Human IgE (hIgE) mAbs against major mite allergen Der p 2 developed using human hybridoma technology were used for IgE epitope mapping and analysis of epitopes associated with the hIgE repertoire.
We sought to elucidate the new hIgE mAb 4C8 epitope on Der p 2 and compare it to the hIgE mAb 2F10 epitope in the context of the allergenic structure of Der p 2.
X-ray crystallography was used to determine the epitope of anti-Der p 2 hIgE mAb 4C8. Epitope mutants created by targeted mutagenesis were analyzed by immunoassays and in vivo using a human high-affinity IgE receptor (FcεRIα)-transgenic mouse model of passive systemic anaphylaxis.
The structure of recombinant Der p 2 with hIgE mAb 4C8 Fab was determined at 3.05 Å. The newly identified epitope region does not overlap with the hIgE mAb 2F10 epitope or the region recognized by 3 overlapping hIgE mAbs (1B8, 5D10, and 2G1). Compared with wild-type Der p 2, single or double 4C8 and 2F10 epitope mutants bound less IgE antibodies from allergic patients by as much as 93%. Human FcεRIα-transgenic mice sensitized by hIgE mAbs, which were susceptible to anaphylaxis when challenged with wild-type Der p 2, could no longer cross-link FcεRI to induce anaphylaxis when challenged with the epitope mutants.
These data establish the structural basis of allergenicity of 2 hIgE mAb nonoverlapping epitopes on Der p 2, which appear to make important contributions to the hIgE repertoire against Der p 2 and provide molecular targets for future design of allergy therapeutics.
使用人杂交瘤技术开发的针对主要螨过敏原 Der p 2 的人 IgE(hIgE)单抗被用于 IgE 表位作图和分析与 hIgE 库相关的表位。
我们旨在阐明 Der p 2 上新型 hIgE 单抗 4C8 的表位,并在 Der p 2 的变应原结构背景下将其与 hIgE 单抗 2F10 的表位进行比较。
使用 X 射线晶体学来确定抗 Der p 2 hIgE 单抗 4C8 的表位。通过免疫测定和体内实验,使用人高亲和力 IgE 受体(FcεRIα)转基因小鼠模型的被动全身性过敏反应,分析通过靶向诱变产生的表位突变体。
与 hIgE 单抗 4C8 Fab 结合的重组 Der p 2 的结构在 3.05 Å 处确定。新鉴定的表位区域与 hIgE 单抗 2F10 表位或被 3 个重叠的 hIgE 单抗(1B8、5D10 和 2G1)识别的区域不重叠。与野生型 Der p 2 相比,单或双 4C8 和 2F10 表位突变体结合的来自过敏患者的 IgE 抗体减少了多达 93%。通过 hIgE 单抗致敏的人类 FcεRIα 转基因小鼠,当用野生型 Der p 2 挑战时易发生过敏反应,当用表位突变体挑战时,不能再交联 FcεRI 以诱导过敏反应。
这些数据确定了 2 个 hIgE 单抗非重叠表位在 Der p 2 上的变应原性的结构基础,这些表位似乎对针对 Der p 2 的 hIgE 库做出了重要贡献,并为未来的过敏治疗药物设计提供了分子靶标。